ATE252572T1 - 5-ht1f agonisten - Google Patents

5-ht1f agonisten

Info

Publication number
ATE252572T1
ATE252572T1 AT99931907T AT99931907T ATE252572T1 AT E252572 T1 ATE252572 T1 AT E252572T1 AT 99931907 T AT99931907 T AT 99931907T AT 99931907 T AT99931907 T AT 99931907T AT E252572 T1 ATE252572 T1 AT E252572T1
Authority
AT
Austria
Prior art keywords
ht1f agonists
ht1f
agonists
mammal
activating
Prior art date
Application number
AT99931907T
Other languages
English (en)
Inventor
Sandra Ann Filla
Daniel James Koch
Brian Michael Mathes
Vincent Patrick Rocco
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE252572T1 publication Critical patent/ATE252572T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99931907T 1998-06-30 1999-06-25 5-ht1f agonisten ATE252572T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9119898P 1998-06-30 1998-06-30
PCT/US1999/014400 WO2000000487A1 (en) 1998-06-30 1999-06-25 5-ht1f agonists

Publications (1)

Publication Number Publication Date
ATE252572T1 true ATE252572T1 (de) 2003-11-15

Family

ID=22226571

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99931907T ATE252572T1 (de) 1998-06-30 1999-06-25 5-ht1f agonisten

Country Status (9)

Country Link
US (1) US6358972B1 (de)
EP (1) EP1089993B1 (de)
JP (1) JP2002519348A (de)
AT (1) ATE252572T1 (de)
AU (1) AU4831899A (de)
CA (1) CA2336254A1 (de)
DE (1) DE69912279T2 (de)
ES (1) ES2209462T3 (de)
WO (1) WO2000000487A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696439B1 (en) * 1999-02-26 2004-02-24 Eli Lilly And Company 5-HT1F agonists
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
HK1054393B (en) * 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h-吲唑化合物
CA2453537A1 (en) 2001-08-08 2003-02-20 Pharmacia & Upjohn Company Therapeutic 1h-pyrido¬4,3-b|indoles
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
MXPA05011223A (es) * 2003-04-18 2006-01-26 Lilly Co Eli Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
DE602004008338T2 (de) 2003-12-17 2008-05-29 Eli Lilly And Co., Indianapolis Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
ZA200709038B (en) 2005-04-13 2009-01-28 Neuraxon Inc Substituted indole compounds having nos inhibitory activity
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CN101466709B (zh) 2006-04-13 2013-03-20 轴突公司 具有nos抑制活性的1,5和3,6-取代的吲哚化合物
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
HUE025471T2 (hu) 2008-04-16 2016-03-29 Karobio Ab Új ösztrogén receptor ligandumok
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
CN102753171A (zh) 2009-04-02 2012-10-24 科鲁西德制药公司 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
CA2819373A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
JP2014510105A (ja) 2011-03-22 2014-04-24 アムジエン・インコーポレーテツド Pim阻害剤としてのアゾール化合物
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
KR102601972B1 (ko) 2015-02-11 2023-11-13 선오비온 파마슈티컬스 인코포레이티드 중추 신경계 질환을 치료하기 위한 1-헤테로사이클릴 이소크로만일 화합물 및 유사체
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
PT3494119T (pt) 2016-07-29 2024-12-10 Pgi Drug Discovery Llc Compostos e composições e seus usos
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
EP3938045A1 (de) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salze einer isochromanylverbindung und kristalline formen, verfahren zur herstellung, therapeutische verwendungen und pharmazeutische zusammensetzungen davon
TWI829107B (zh) 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體,以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
EP0494774A1 (de) * 1991-01-11 1992-07-15 MERCK SHARP & DOHME LTD. Indazol-substituierte 5-Kettenglieder heteroaromatische Verbindungen
TW263508B (de) 1991-02-12 1995-11-21 Pfizer
GB9226537D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9407447D0 (en) * 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
US6358972B1 (en) 2002-03-19
ES2209462T3 (es) 2004-06-16
WO2000000487A1 (en) 2000-01-06
AU4831899A (en) 2000-01-17
JP2002519348A (ja) 2002-07-02
CA2336254A1 (en) 2000-01-06
DE69912279T2 (de) 2004-07-29
EP1089993A1 (de) 2001-04-11
EP1089993B1 (de) 2003-10-22
DE69912279D1 (de) 2003-11-27

Similar Documents

Publication Publication Date Title
ATE252572T1 (de) 5-ht1f agonisten
ATE377000T1 (de) 5-ht1f agonisten
ATE273305T1 (de) Thrombin-inhibitoren
NL300877I2 (nl) obeticholzuur
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
MY123908A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof
EA200000871A1 (ru) Ингибиторы фосфолипазных ферментов
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
DE60120748D1 (de) 3-substituierte oxindolderivate als beta-3-agonisten
ATE284879T1 (de) Indazol-derivate als 5-ht1f agonists
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
BR0313846A (pt) Derivados de dioxano-2-alquilcarbamatos, sua preparação e sua aplicação em terapêutica
WO2000000490A3 (en) 5-ht1f agonists
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
ES2011919A6 (es) Metodo para producir compuestos antagonistas de los leucotrienos.
NO20014127L (no) 5-HT1F agonister
HU9800970D0 (en) Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
DE69524064D1 (de) Indan-2-mercaptoacetylamid disulfidderivate als enkephalinase inhibitoren
EA200001107A1 (ru) ПРОИЗВОДНЫЕ ОКТАГИДРО-6,10-ДИОКСО-6H-ПИРИДАЗИНО [1,2-a] [1,2] ДИАЗЕПИН-1-КАРБОНОВОЙ КИСЛОТЫ, СПОСОБ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТЕРАПЕВТИЧЕСКИ АКТИВНЫХ СОЕДИНЕНИЙ
YU43499A (sh) Kristalna hidratovana natrijumova so (e)-4,6-dihloro-3- (2-okso-1-fenilpirolidin-3-iliden metil)-1h-indol-2- karboksilne kiseline
ATE248163T1 (de) Neuartige, pharmazeutisch aktive verbindung
BR0008545A (pt) Processo para a preparação de um composto, e, composto
DK118390A (da) Substituerede quinoliner

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties